Previous 10 | Next 10 |
Image source: The Motley Fool. ClearPoint Neuro, Inc. (NASDAQ: CLPT) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: ClearPoint Neuro, Inc. (CLPT) Q2 2022 Earnings Call Transcript
SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice...
SOLANA BEACH, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 second ...
CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval process. While current valuation isn't compelling, long term this should be a winner. Introduction Today I'd like to begin my ...
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted marketing authoriz...
The European Commission (EC) approved PTC Therapeutics' ( NASDAQ: PTCT ) one-time gene replacement therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults. The company said Upstaza (eladocagene exuparvovec) i...
SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patie...
SOLANA BEACH, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the receipt of certification for the Medical Device Single ...
The following slide deck was published by ClearPoint Neuro, Inc. in conjunction with this event. For further details see: Clearpoint Neuro (CLPT) Investor presentations - Slideshow
Covid remains a short-term headwind for ClearPoint Neuro's Functional Neuro Navigation segment. There are 45 biopharma partners versus 40 in the previous quarter. PTC-AADC is to commercialize later in the year. Operating losses have declined, and operational efficiency has improve...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended Ma...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene the...